New York, May 23, 2026, 10:02 (EDT)
- Century Therapeutics last traded at $2.26, flat, as U.S. markets paused for Memorial Day weekend.
- A filing from May 21 amended a resale prospectus for as many as 176.1 million shares. The move didn’t raise the number of shares registered.
- Investors are looking ahead to June 8, when preclinical data for CNTY-813 will be presented at the American Diabetes Association meeting.
Century Therapeutics stock traded flat ahead of the long U.S. holiday break. A new resale filing kept focus on possible stock overhang instead of the company’s latest trial data. Shares of the Philadelphia biotech were last at $2.26. Volume stood around 531,900, putting its market cap close to $437 million.
That’s important since markets are closed for the weekend and Nasdaq will be shut again Monday, May 25, for Memorial Day. The next full session will be Tuesday. Investors will have until then to consider the company’s new SEC filing before trading starts up again.
Century Therapeutics filed an amendment dated May 21 to its prospectus for the potential resale of up to 176,086,947 shares of common stock, counting shares tied to warrants. The company said the change does not add more shares; it just reflects a transfer of shares from Point72 Associates to SILV Fund Ltd.
Simply put, a resale registration allows holders to offer registered shares in the market. That doesn’t mean they’ve sold yet. For a small biotech though, just knowing that many shares could hit the market can weigh on the stock, more so when investors want to see clinical results first.
Century hasn’t posted a new press release to its investor-relations page in the last 48 hours. The most recent update is still the May 13 first-quarter report. Before that, Century put out an April 30 note on a future scientific presentation.
Century is still focused on its cash and runway. The company had $217.0 million in cash, cash equivalents and marketable securities as of March 31, enough to get through the first quarter of 2029. It posted a net loss of $21.6 million in the first quarter, compared to $76.6 million in net income a year ago, when it booked collaboration revenue.
Century CEO Brent Pfeiffenberger said the company is “executing our pipeline with discipline” and singled out CNTY-813, its type 1 diabetes program. CNTY-813 uses induced pluripotent stem cells, or iPSCs. These are lab-made cells that can turn into other cell types. The therapy is meant to be an off-the-shelf islet replacement.
Century Therapeutics said it plans to file an investigational new drug application for CNTY-813 in the fourth quarter of 2026, aiming to start human trials then. Early clinical data could come in the second half of 2027, if the drug passes the rest of its preclinical and regulatory hurdles.
The week wrapped up with Century Therapeutics showing up at the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 19, but there was no major company announcement out of that. The focus for the stock was still on the May 21 resale-prospectus supplement.
Quiet week for scheduled news, but a key event lands soon. Century will present CNTY-813 preclinical data June 8 at the ADA 86th Scientific Sessions in New Orleans. In April, Pfeiffenberger said the program is being built with “scalability and patient access” as priorities. GlobeNewswire
Rivals are moving ahead. Vertex Pharmaceuticals said its zimislecel, an investigational stem-cell-derived islet therapy for type 1 diabetes, showed lasting one-year effects in a small trial, but patients need ongoing immunosuppressive drugs. In April, Sana Biotechnology said it is partnering with Mayo Clinic to develop SC451, a hypoimmune-modified pancreatic islet-cell therapy designed to avoid both insulin and immunosuppression.
The wider market didn’t offer much direction. The SPDR S&P Biotech ETF slipped on its most recent tick, and the iShares Nasdaq Biotechnology ETF was down just a touch. Trading stayed calm, leaving the stage to a microcap biotech usually moved by its own filings, funding news and clinical readouts, not by what the indexes are doing.
Downside risk looks clear. Century said in its latest filing it’s still early-stage, expects continued losses, and might have to raise more cash. There’s also uncertainty in preclinical steps, trials, regulatory reviews, outside manufacturing and competition. Trouble for CNTY-813, a bigger resale overhang, or tighter capital markets could hit the shares, despite a cash runway into 2029.
